Nurix Therapeutics Inc. NRIX
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Nurix Therapeutics Inc. is a biotechnology firm focused on developing therapies to address immune system disorders and cancers. At the heart of its innovative approach is the modulation of protein levels within cells, a critical factor in disease progression. Nurix employs its proprietary DELigase platform to discover …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees317
TickerNRIX
Statistics
Market Cap$1.82B
Revenue (TTM)$84.0M
Net Income-$264.5M
Net Margin-314.9%
EPS$-3.05
P/E-5.56
P/S24.46
P/B3.65
EV/EBITDA-3.58
ROE-61.4%
Dividend Yield—
Price$17.59
Data: Twelve Data · Revenue = mcap / P/S